Many employers hold off on coverage of Wegovy and similar drugs amid cost concerns and the prospect of cheaper options down the road
Read Full Story
Latest posts by Market Watch (see all)
- Maine bars Trump from presidential primary ballot, citing insurrection clause - December 28, 2023
- These ETF strategies were big winners in 2023. Here’s where one CFRA analyst sees them going next year. - December 28, 2023
- Google settles $5 billion consumer-privacy lawsuit: report - December 28, 2023